Cyberknife Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Liver: Preliminary Results
Figure 1
Tumor response in patients with nonresectable liver tumors treated with Stereotactic Body Radiation Therapy (SBRT). All patients with hepatocellular carcinoma (HCC) responded to SBRT with a mean decrease in tumor volume of 60% at 3 months after therapy ( by paired -test). Similar response was observed in patients with liver metastases (LMs) treated with SBRT with a mean decrease tumor volume of 59% at 3 months posttreatment ( by paired -test). It was difficult to be certain of the tumor response of patients with intrahepatic cholangiocarcinoma (IHC) due to the multicentricity of these tumors and the ill-defined edges.
